BOC Sciences is responsible for ADC quality research including ADC drug identification, specification, content, purity, safety and quality analysis and method development, validation and testing.

Antibody-Drug Conjugates (ADCs) are a new class of biopharmaceuticals made by coupling monoclonal antibodies and small-molecule drugs with strong cytotoxicity through biologically active linkers. The following problems arise during the preparation of commonly used antibody-conjugated drugs:

• Some antibodies cannot be successfully coupled with small-molecule drugs.
• There are multiple binding sites (Cys, Lys residues, etc.) in the antibody, and the difference of binding sites and binding amount will lead to heterogeneity.
• Due to the higher hydrophobicity of small molecule drugs, the difference of binding amount with monoclonal antibodies may lead to the change of hydrophobicity of ADC drugs.